Encouragingly, early phase studies combining inhibitors of downstream signalling targets of PI3K with radiotherapy, such as the AKT inhibitor nelfinavir, have reported promising response rates and outcomes in rectal and pancreatic cancer [26], [27], [28]. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.